Sutro Biopharma presents preclinical data across its pipeline of ADCs

Sutro Biopharma (STRO) announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research, AACR, Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor, were reviewed in an oral presentation titled “STRO-004, an exatecan-based next-generation tissue factor-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial.” In the preclinical study, STRO-004 demonstrated robust and consistent antitumor activity across a broad range of TF-expressing solid tumor patient-derived xenograft models, with improved efficacy compared to benchmark ADCs. At a single, clinically relevant dose of 5 mg/kg, STRO-004 achieved remarkable disease control and tumor reduction across multiple tumor types. STRO-004’s favorable tolerability, with a highest non-severely toxic dose of 50 mg/kg, and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting the Company’s belief that STRO-004 will demonstrate superior depth and durability of response in the clinic.